记者丨曾静娇 编辑丨刘雪莹 3月5日早盘，亚太股市主要股指集体反弹。 A股、港股指数走强； 日经225指数上涨2.7%，日内拉涨超1400点；韩国综合指数 涨超10%，盘中 短暂触发熔断，三星电子、SK海力士涨超10%。 （回顾） | 日经225 | 韩国综合 | 新加坡海峡 | | --- | --- | --- | | 55713.27 | 5617.45 | 4844.93 | | +1467.73 +2.71% +523.91 +10.29% +32.18 +0.67% | | | | 澳洲标普200 | 印度 | MSCI台湾 | | 8925.10 | 79116.19 | 1349.18 | | -18.30 -0.20% 0.00 0.00% +42.63 +3.26% | | | | 上证指数 | 深证成指 | 恒生指数 | | 4116.77 | 14150.45 | 25546.63 | | +34.30 +0.84% +232.70 +1.67% +297.15 +1.18% | | | 截至午盘， 上证指数涨近1%， 深成指涨逾1.6%， 创业板指、科创综指涨超2%。全市场超4500 ...

证券代码：300753 证券简称：爱朋医疗 公告编号：2026-004 股东北京章泓私募基金管理有限公司-章泓精选1号私募证券投资基金保证向本 公司提供的信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 江苏爱朋医疗科技股份有限公司（以下简称"公司"）于 2025 年 11 月 12 日在巨潮 资讯网（http://www.cninfo.com.cn）披露了《关于持股 5%以上股东减持股份的预披露公 告》（公告编号：2025-052），持有本公司 7,058,000 股（占公司总股本的 5.60%）的持 股 5%以上股东北京章泓私募基金管理有限公司-章泓精选 1 号私募证券投资基金（以下 简称"章泓基金"），计划自上述公告披露之日起十五个交易日后的三个月内以集中竞 价交易方式减持所持有的本公司股份不超过 1,260,480 股（占公司总股本的 1%）；以大 宗交易方式减持所持有的本公司股份不超过 1,260,480 股（占公司总股本的 1%）。 2026 年 1 月 8 日，公司披露了《关于持股 5%以上股东减持至 5%以下暨权益变 ...

行 业 研 华福证券 这款侧脑室灯笼电极在功能上表现亮眼，在记忆引导决策的动物 实验中，其构建的分类模型预测准确率最高近 98%，显著优于传统皮 层电极，还能捕获更多与记忆、决策相关的神经区域信息。该研究从 植入位置和电极结构双维度创新，为提升侵入式脑机接口长期稳定性 提供了新技术方向，也为获取深部认知相关信息开辟了新路径，其提 出的"脑室通路"概念为脑机接口设计提供新参考，未来该技术还需 在器件优化、人体适配等方面进一步验证。 "十五五"重点赛道，脑机接口市场规模有望快速增长 根据 precedence research，2024 年全球脑机接口市场规模约为 26.2 亿美元，预计 2025 年将达到 29.4 亿美元，到 2034 年有望增长至 124 亿美元，十年间复合年增长率为 17.35%；据工信微报，2024 年中国脑 机接口市场规模为 32.0 亿元，预计到 2028 年将达 61.4 亿元。《中共 中央关于制定国民经济和社会发展第十五个五年规划的建议》提出前 瞻布局未来产业，推动脑机接口等成为新的经济增长点。这些产业蓄 势发力，未来 10 年将再造一个中国高技术产业。 华福证券 建议关注 机械 ...

Group 1 - In February, nearly 240 listed companies were surveyed by various institutions, with over half achieving positive returns during the same period, and some stocks seeing cumulative gains exceeding 80% [1] - The mechanical equipment and electronics sectors were the primary focus of institutional surveys, with significant attention also given to cyclical sectors like basic chemicals [1] - Institutions are optimistic about investment opportunities in humanoid robots, upstream AI infrastructure, and certain chemical sector stocks that offer high elasticity and dividends [1] Group 2 - In January 2026, domestic automobile sales reached 2.346 million units, with the top ten companies accounting for 1.962 million units, representing 83.6% of total sales, indicating a high concentration in the market [2] - The automotive market is characterized by "steady start and structural differentiation," with increased competition among top manufacturers as they launch new products and technologies [2] - The pharmaceutical and biotechnology sectors saw 80 companies receive institutional surveys, with a focus on brain-computer interface stocks and the trend of innovative drugs going global [2] Group 3 - Several securities firms have held spring strategy meetings earlier than usual, reflecting changes in the competitive landscape of the industry [3] - The shift from "commission for research" to "service for income" is becoming more pronounced among brokerage firms [3] - The AI industry is entering a more pragmatic phase, focusing on revenue and profit, with significant investment opportunities in AI inference computing and domestic AI chips [3] Group 4 - Lithium carbonate futures surged by 11.83% to a high of 187,700 yuan/ton, driven by Zimbabwe's adjustments to lithium export policies, which may tighten global supply in the short term [4] - UBS predicts a potential third price cycle for lithium, raising the average price expectation for 2026 to around 180,000 yuan/ton [4] Group 5 - The A-share merger and acquisition market remains vibrant, with over 500 transactions disclosed since the beginning of the year, totaling over 100 billion yuan [5] - More than 50% of these transactions are driven by industrial synergy, highlighting a core market trend [5] - The hard technology sector is a primary battleground for mergers and acquisitions, with increased participation from the Sci-Tech Innovation Board and the Growth Enterprise Market [5] Group 6 - The Hong Kong Stock Exchange reported record highs in trading volume and revenue for 2025, reaffirming its position as a global leader in new stock financing [6] - The exchange aims to enhance market convenience and competitiveness while continuing to invest strategically in emerging business areas [6] - Export-oriented companies are actively implementing measures to hedge against currency risks amid fluctuations in the renminbi exchange rate [6] Group 7 - Regions like Guangdong, Anhui, and Hubei are strategically positioning themselves in advanced fields such as AI, quantum technology, and high-end manufacturing [7] - The development of future industries relies heavily on original innovation and disruptive technologies, which are still in early stages [7] - Policies are increasingly systematic and comprehensive, supporting innovation from inception to market application [7] Group 8 - NIO's chip subsidiary, Anhui Shenji Technology Co., completed its first round of equity financing, raising 2.257 billion yuan, with a post-investment valuation nearing 10 billion yuan [8] - The financing attracted diverse capital participation, including state-owned capital and semiconductor industry funds, indicating market confidence in the company's technology and production capabilities [8] - The involvement of local state capital aligns with Hefei's ongoing investment in the integrated circuit industry [8]

Core Insights - The pharmaceutical and biotechnology sector is experiencing increased institutional interest, particularly in brain-computer interface (BCI) stocks, driven by advancements in technology and commercialization efforts [1][2][3] Group 1: Brain-Computer Interface (BCI) Stocks - BCI stocks such as Xiangyu Medical, Aipeng Medical, and Meihao Medical have attracted significant institutional attention, with Xiangyu Medical receiving 208 institutional inquiries, Aipeng Medical 177, and Meihao Medical 125 [1] - Xiangyu Medical plans to upgrade 27 core products by mid-2026 and aims to launch nearly 100 BCI products by the end of 2026, focusing on multi-modal and multi-paradigm applications [2] - Aipeng Medical emphasizes the rapid growth of the BCI industry, particularly in non-invasive applications, and is prioritizing commercialization strategies based on existing technologies and channels [2] - Meihao Medical aims to be a key supplier in the BCI field, enhancing its competitive edge in invasive BCI implants through increased R&D investment and collaboration with clients [2][3] Group 2: Globalization of Pharmaceutical Companies - Domestic pharmaceutical companies are focusing on global strategies, with an emphasis on the commercialization of innovative drugs abroad [4][5] - MediXis has established a 2,000 square meter R&D office in Boston to support its global strategy, with overseas revenue expected to account for approximately 47% of total income by 2025 [4] - Huayuan Pharmaceutical has set up multiple business and R&D centers globally, with overseas revenue reaching 43% of total income in the first half of 2025 [4][5] - The "innovation + internationalization" strategy remains a core focus for the sector, with increasing participation of Chinese companies in global pharmaceutical collaborations [6]

本文核心数据：脑机接口领域细分市场情况;脑机接口领域侵入式脑机接口分析 1、中国脑机接口行业细分市场情况 脑机接口按照信号采集方式可以通常分为侵入式、半侵入式和非侵入式三大类别。目前侵入式脑机接口 的研究主要集中在开发新型材料以及更精细的电极以提高生物相容性，非侵入式产品研究主要集中在改 进材料以提升电极导电率、改进结构以促进电极与皮肤充分接触。较多公司侧重开发非侵入式产品，涉 及教育和泛娱乐、健康和睡眠辅助等。在侵入式领域内深耕的国内公司为数不多，少量公司正在开发无 创或微创的产品与解决方案，以用来进行脑科学研究、精神与心理疾病筛查，各类神经系统疾病监护、 诊疗与康复。 转自：前瞻产业研究院 以下数据及分析来自于前瞻产业研究院脑机接口研究小组发布的《全球及中国脑机接口（BCI）行业发 展前景展望与投资机遇分析报告》。 行业主要上市公司：翔宇医疗(688626)、岩山科技(002195)、科大讯飞(002230)、伟思医疗(688580)、爱 朋医疗(300753)、三博脑科(301293)、创新医疗(002173)等 2、侵入式脑机接口分辨率高 侵入式脑机接口指通过神经外科手术将电极等信号记录装置植入脑内特 ...

Core Insights - The article highlights the increasing focus of institutional investors on hard technology breakthroughs and performance certainty for investment opportunities in 2026 [4] Group 1: Institutional Research Trends - In late 2025 to early 2026, institutions conducted research on approximately 1,162 companies, with a total of 30,000 receptions from listed companies across various core industries [3] - The shift in focus from merely gathering data to understanding practical applications indicates a significant change in investment strategies [9] Group 2: Brain-Computer Interface (BCI) Focus - Brain-computer interface technology has emerged as a key area of interest, with companies like Xiangyu Medical, Aipeng Medical, and Meihao Medical frequently hosting inquiries from fund managers [5][6] - Institutions are particularly interested in the depth of collaboration with innovative BCI clients and the feasibility of mass production [7][8] Group 3: AI Computing Power and Applications - The focus on artificial intelligence has shifted from foundational models to the iteration of computing power and practical applications [10] - Companies like Zhongji Xuchuang attracted attention for their 1.6T optical module orders and technology advancements, reflecting a market shift towards evaluating technological iteration speed [10] Group 4: Commercial Aerospace and Semiconductor Focus - Commercial aerospace has gained significant attention, with institutions exploring various segments such as rocket manufacturing and satellite components [17] - In the semiconductor sector, institutions are focused on overcoming technical barriers, with companies like Haimei Information and Huaren Micro receiving extensive inquiries regarding their advanced process products [22][23] - The trend of institutions closely monitoring companies with promising earnings forecasts indicates a more rational investment approach, seeking high-quality targets with core competitiveness [26]

股票近期走势 股票价格近期呈现波动，受脑机接口板块情绪影响。2026年2月11日，爱朋医疗股价下跌1.11%，成交 额1.18亿元，主力资金净流出。而2026年2月6日，股价曾上涨4.13%，当日收盘报34.57元，受脑机接口 概念催化资金流入。最新数据显示，截至2026年2月12日，股价为33.39元，较前一日上涨1.37%，成交 额1.01亿元，但近5日累计下跌3.41%，反映短期市场分化。 以上内容基于公开资料整理，不构成投资建议。 经济观察网近7天内，爱朋医疗（300753）的主要热点围绕脑机接口业务进展和机构调研关注。2026年2 月11日，公司在投资者互动平台表示，麻醉穿刺机器人项目仍处于设计开发阶段，暂无重大突破。同 时，根据新快报2026年2月5日的报道，脑机接口成为机构调研重点，爱朋医疗在调研中介绍了脑电技术 和脑状态前沿研究的商业化进展，凸显该领域受政策支持和技术突破驱动。 ...

智冉医疗解决脑机接口安全性难题，脑机接口作为顶层战略稳步推进 2月9日上午，书记在北京国家信创园考察科技创新工作，接见北京脑科学与类脑研究所的所长罗敏敏等代表。 1月30日，中共中央政治局举行第二十四次集体学习，脑机接口作为"十五五"六大未来产业被重点学习。 我国高通量、可拉伸柔性电极解决行业痛点 北京脑科学与类脑研究所资深研究员、智冉医疗创始人方英领衔的团队，研制 智冉医疗解决脑机接口安全性难题，脑机接口作为顶层战略稳步推进 北京脑科学与类脑研究所资深研究员、智冉医疗创始人方英领衔的团队，研制出一款高通量、可拉伸柔性电极， 该技术解决了传统柔性电极在大脑动态运动时易移位、易脱出的核心问题，为植入式脑机接口长期稳定性提供了 底层解决方案，该成果于2月5日在《NatureElectronics》发表。 国产脑机全链布局，比肩甚至超越Neuralink 马斯克创办的Neuralink公司，首例人体植入术后数周，高达85%的柔性电极丝从该患者的脑组织中脱出。 智冉医疗已拥有电极植入手术机器人及微纳加工车间，可拉伸柔性电极达1024通道，实现从技术路径到工程参 数，比肩甚至超越Neuralink。 受益标的：创新医疗 ...

智通财经APP获悉，浙商证券发布研报称，马斯克旗下Neuralink首款产品Telepathy预计在今年量产，目 前超10000人申请体验。Neuralink现估值超90亿美金，公司愿景是增加沟通带宽，提高交流效率，联接 人脑与AI。在未来，假设交流带宽将成为生物与技术之间的瓶颈，普通人将通过脑机接口实现与AI的 交流和复杂机械的操控。政策端，我国脑计划十年规划(2021-2030)进入下半场关键落地期，脑机接口成 为新质生产力未来产业之一，迎政策东风。建议关注脑机接口与大模型、具身智能技术深入融合。 浙商证券主要观点如下： Neuralink的首款产品Telepathy(心灵感应)预计在今年量产，目前超10000人申请体验 Telepathy聚焦"大脑功能正常，但运动/交流通路断裂"的重症群体，例如脊髓损伤、渐冻症患者。量产 的三个重要条件——N1性能提升、手术安全性提升、成本降低：1)预计2026年N1设备电极数量从1000 个增加到3000个，提升神经信号的接收量。2)针对手术流程，未来将直接穿过包裹大脑的硬脑膜植入电 极线的技术，可降低手术的侵入性，减少风险，降低感染隐患。3)第二代设备将电极植入速度 ...